Hormone Therapy in Perimenopause: Separating Fear from Evidence
If I had a dollar for every time a patient walked into my office and said "I don't want to go on hormones" before I'd even mentioned them — I'd have a very comfortable retirement fund.
I get it. For over two decades, women have been told that hormone therapy is dangerous. Linked to breast cancer. Heart attacks. Blood clots. That fear didn't come from nowhere — it came directly from the Women's Health Initiative (WHI) study, published in 2002, which sent shockwaves through medicine almost overnight. Doctors stopped prescribing. Women stopped asking. And a generation of perimenopausal women was left to white-knuckle their way through hot flashes, insomnia, brain fog, and mood swings while being told it was just "a normal part of aging."
Here's the thing: that narrative is outdated. And it's time we replaced it with something more accurate.
What the Research Actually Shows
The WHI study had significant design problems that rarely made the headlines.
The average participant was 63 years old — more than a decade past menopause. Many had pre-existing cardiovascular risk factors. The estrogen used was oral conjugated equine estrogen, combined with a synthetic progestin called medroxyprogesterone acetate (MPA). The route of delivery, the timing, and the type of hormone all matter enormously to outcomes — and none of that nuance survived the media cycle.
What updated research has shown us since is that timing is everything. When women start hormone therapy before age 60 or within 10 years of their last period — what researchers now call the "window of opportunity" — the risk profile looks completely different. In that window, hormones aren't just safe for most women. They're actually protective for brain health, bone density, and cardiovascular function.
The North American Menopause Society's 2022 position statement reflects this clearly: for most healthy, symptomatic women under 60 and within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks.
That's a very different story than what most women have been carrying around for twenty years.
What's Happening in Your Body
Perimenopause usually begins in the early-to-mid 40s, though it can start earlier. It's not a single event — it's a multi-year hormonal transition where progesterone tends to drop first, and then estrogen starts fluctuating erratically before eventually declining. Think of it less like a light switch and more like a dimmer that someone keeps adjusting without telling you.
Those fluctuations are what drive the symptoms most women chalk up to "just getting older":
Disrupted sleep and waking at 3am for no reason
Anxiety that appears out of nowhere
Brain fog and memory blips
Irregular periods and heavier flow
Hot flashes and night sweats
Joint pain and low libido
Changes in cholesterol
Vaginal dryness that no amount of water intake seems to fix
These aren't character flaws or signs you're falling apart. They're physiological responses to a hormonal environment in flux.
And here's what concerns me as an ND: some of the changes happening during this time — to bone density, cardiovascular risk, and cognitive function — are happening quietly in the background long before symptoms become unbearable. Perimenopause is a critical window not just for symptom management, but for long-term disease prevention.
The Breast Cancer Question
This is the question I get most often, and it deserves a real answer — not a dismissal, and not unnecessary alarm.
Here's the nuance that almost never makes it into the conversation: the breast cancer risk associated with HRT in the original WHI study was driven by the synthetic progestin (MPA) used in the study, not by estrogen alone, and not by bioidentical progesterone. When the estrogen-only arm of the WHI was analyzed separately — women who had a hysterectomy and took estrogen without a progestogen — there was actually no increased breast cancer risk, and some data even suggested a protective effect.
The real distinction lies in which progestogen is used. The large French E3N cohort study, which followed over 80,000 women, found that women using estrogen combined with synthetic progestins had a significantly elevated breast cancer risk. Women using estrogen combined with micronized progesterone — the bioidentical form — did not. Their relative risk was essentially the same as women not on hormones at all. A systematic review published in Climacteric in 2018, evaluating 19 studies, confirmed this: estrogen combined with micronized progesterone does not appear to increase breast cancer risk for up to five years of use. Beyond five years, the data gets thinner, and ongoing monitoring becomes especially important.
This is not a trivial distinction. It changes the entire risk calculus — and it's why the type of hormone prescribed matters as much as whether hormones are prescribed at all.
Who Might Benefit from Hormone Therapy
This is where individualized care matters more than any blanket recommendation. Hormone therapy isn't right for everyone, and the conversation is always more nuanced than "yes" or "no."
Women who tend to be good candidates are typically under 60 or within 10 years of menopause onset, experiencing significant vasomotor symptoms, sleep disruption, mood changes, or genitourinary symptoms that are affecting quality of life — and who don't have contraindications like certain hormone-sensitive cancers, active blood clot history, or uncontrolled cardiovascular disease.
Route of delivery also matters. Transdermal estrogen — patches, gels, or sprays applied to the skin — bypasses the liver's first-pass metabolism, which means a lower clotting risk compared to oral estrogen. For women with elevated cardiovascular risk, that distinction is clinically significant.
How I Approach Hormone Prescribing
In my practice, I don't prescribe hormones based on a symptom checklist alone. A thorough intake includes a detailed hormone panel, thyroid function, metabolic markers, bone density when appropriate, a personal and family health history, and a real conversation about what's actually disrupting your life.
Because sometimes the answer is hormones — and sometimes it's addressing sleep first, or stress load, or gut health, or nutritional gaps. Often it's a combination of all of the above. Naturopathic medicine isn't about choosing between "natural" and "conventional." It's about using the best available evidence to build a plan that fits the actual person sitting across from me.
When hormones are appropriate, I prefer bioidentical estradiol and micronized progesterone — forms that more closely mirror what your body makes and carry a more favorable safety profile than their synthetic counterparts. That said, compounded hormones and conventional options both have a place, and the right choice depends on the individual.
What I don't want is for fear — especially fear rooted in a misread, 20-year-old study — to be the reason a woman doesn't access a treatment that could meaningfully improve her health and her life.
If you're in your 40s and something feels off — even if your labs keep coming back "normal" — you deserve a conversation that goes deeper than being told to wait and see. I'd be glad to be that conversation.
This post is for educational purposes only and does not constitute medical advice. Hormone therapy is not appropriate for everyone. Please work with a qualified healthcare provider who knows your individual health history before making any treatment decisions.
References
The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028
Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353–1368. doi:10.1001/jama.2013.278040
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment. 2008;107(1):103–111. doi:10.1007/s10549-007-9523-x
Stute P, Wildt L, Neulen J. The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric. 2018;21(2):111–122. doi:10.1080/13697137.2017.1421925
Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. doi:10.1136/bmj.e6409
Mosconi L, Berti V, Quinn C, et al. Sex differences in Alzheimer risk: brain imaging of endocrine vs chronologic aging. Neurology. 2017;89(13):1382–1390. doi:10.1212/WNL.0000000000004425
Bluming AZ, Tavris C. Estrogen Matters. New York: Little, Brown Spark; 2018.
